HONG KONG – South Korea is actively working to expand its artificial intelligence (AI) capabilities in health care, but outdated regulations and concerns over privacy and profit sharing are proving to be significant stumbling blocks.
HONG KONG – With an aging population and a shortage of doctors, Japan is now working to develop artificial intelligence (AI)-based medicine faster than any other country in Asia.
South Korean biotech Toolgen Inc., based in Seoul, has signed an agreement with another Korean biomedical startup, Nsage Inc., based in Incheon, to cooperate on gene-edited cell line R&D and commercialization.
HONG KONG – South Korean biotech venture Crystal Genomics Inc., based in Seongnam City, Gyeonggi-do, said it signed a memorandum of understanding for a strategic partnership with Bellevue Asset Management AG, a global asset manager headquartered in Küsnacht, Switzerland.
HONG KONG – Following a regulatory committee's ruling that three of four deaths previously reported during a phase II trial were unrelated to the study drug, South Korea's Ministry of Food and Drug Safety (MFDS) cleared Yuhan Corp. to continue testing lazertinib (YH-25448) in the non-small-cell lung cancer (NSCLC) study.
HONG KONG – Following a regulatory committee's ruling that three of four deaths previously reported during a phase II trial were unrelated to the study drug, South Korea's Ministry of Food and Drug Safety (MFDS) cleared Yuhan Corp. to continue testing lazertinib (YH-25448) in the non-small-cell lung cancer (NSCLC) study.
